ストックスクリーナーアプリを入手
3.19
5.63%
0.17
アフターアワーズ：
3.21
0.02
+0.63%
前日終値:
$3.02
開ける：
$3.03
24時間の取引高:
507.36K
Relative Volume:
0.78
時価総額：
$115.29M
収益：
$160.43M
当期純損益:
$-227.64M
株価収益率:
-0.0464
EPS:
-68.77
ネットキャッシュフロー:
$-170.79M
1週間 パフォーマンス:
-5.34%
1か月 パフォーマンス:
-3.63%
6か月 パフォーマンス:
-46.48%
1年 パフォーマンス:
-11.39%
1日の値動き範囲:
$3.00
$3.20
1週間の範囲:
$2.95
$3.55
52週間の値動き範囲:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
AGEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.19 | 109.15M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | 開始されました | Robert W. Baird | Outperform |
| 2023-02-28 | 再開されました | H.C. Wainwright | Buy |
| 2022-09-28 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 再開されました | B. Riley FBR | Buy |
| 2019-04-22 | 開始されました | B. Riley FBR | Buy |
| 2016-10-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | 繰り返されました | Maxim Group | Buy |
| 2016-03-11 | アップグレード | Maxim Group | Hold → Buy |
| 2015-12-16 | 開始されました | Jefferies | Buy |
| 2015-10-27 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-07-27 | 繰り返されました | MLV & Co | Buy |
| 2015-06-11 | 開始されました | Oppenheimer | Outperform |
| 2015-01-12 | 繰り返されました | Maxim Group | Buy |
| 2015-01-09 | 繰り返されました | MLV & Co | Buy |
| 2015-01-09 | 繰り返されました | Maxim Group | Buy |
| 2014-12-19 | 繰り返されました | Maxim Group | Buy |
| 2014-05-08 | 繰り返されました | Maxim Group | Buy |
| 2014-03-14 | 繰り返されました | MLV & Co | Buy |
| 2013-10-08 | 繰り返されました | Maxim Group | Buy |
| 2012-01-05 | 開始されました | William Blair | Outperform |
| 2011-12-01 | 開始されました | Global Hunter Securities | Buy |
すべてを表示
Agenus Inc (AGEN) 最新ニュース
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
Colorectal Cancer is Moving in the Wrong Direction – Agenus - Oncodaily
Agenus Strengthens Medical Affairs Infrastructure to Support Growing Authorized Access to Botensilimab–Balstilimab - Oncodaily
Agenus Lands $141M Zydus Partnership to Power BOT+BAL and U.S. Manufacturing Expansion - Oncodaily
Expansion of Global Medical Affairs to Support BOT+BAL Access – Agenus - Oncodaily
Agenus expands medical affairs to support early access to cancer therapy By Investing.com - Investing.com Nigeria
Looking Into Agenus Inc's Recent Short Interest - Benzinga
Agenus expands medical affairs to support early access to cancer therapy - Investing.com
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program - Intellectia AI
Agenus to Host First 2026 Stakeholder Webcast - The AI Journal
Agenus signals expanded access and 2026 plans - Traders Union
Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest - MarketBeat
FY2030 Earnings Estimate for Agenus Issued By HC Wainwright - MarketBeat
Agenus (AGEN) Q1 2025 Earnings Call Transcript - AOL.com
Zydus Completes Agenus Deal, Launches US-Based Biologics CDMO Arm Zylidac Bio - Medical Dialogues
Bear Alert: How sensitive is Agenus Inc to inflationJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Agenus Forms Major Strategic Collaboration with Zydus Lifesciences - TipRanks
Agenus Announces the Closing of $141M Strategic Collaboration with Zydus Group - Oncodaily
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal - Yahoo Finance
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - 뉴스와이어
Agenus closes strategic collaboration with Zydus Lifesciences By Investing.com - Investing.com Nigeria
Zydus LifeSciences Acquires Biologics Manufacturing Facilities from Agenus - Contract Pharma
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences - BioPharm International
Agenus Falls After $141 Million Zydus Deal Closes - marketscreener.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Zydus Completes Agenus Biologics Facilities Acquisition And Launches U.S. CDMO Unit - Pulse 2.0
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - StreetInsider
New Zylidac Bio sites help secure U.S. biologic drug supply chains - Stock Titan
Agenus closes strategic collaboration with Zydus Lifesciences - Investing.com
Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing - scanx.trade
Cancer combo shows 42% 2yr survival as $141M immunotherapy deal closes - Stock Titan
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer - Investing.com Nigeria
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer By Investing.com - Investing.com South Africa
Agenus Consolidates Financial Leadership With Interim CFO Appointment - TipRanks
Agenus Inc. Appoints Austin Charette as Principal Accounting Officer, Effective January 8, 2026 - marketscreener.com
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas - 뉴스와이어
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Why Agenus Inc. stock is a must watch in 20252025 Geopolitical Influence & Reliable Price Breakout Alerts - Улправда
What risks investors should watch in Agenus Inc. stockEarnings Overview Summary & Daily Stock Trend Reports - Улправда
Is Agenus Inc. stock attractive for income investorsNew Guidance & Low Risk Entry Point Guides - Улправда
Will Agenus Inc. stock sustain high P E ratiosJuly 2025 Setups & Community Verified Swing Trade Signals - Улправда
Agenus amends Ligand agreement, modifies warrant holder rights - TipRanks
How geopolitical tensions affect Agenus Inc. stockMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Agenus Inc (AGEN) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):